The targeting of the sole cyclin D1 is not adequate for mantle cell lymphoma and myeloma therapies

Haematologica

Volumn 94, Issue 12, 2009, Pages 1781-1782

  Tchakarska, Guergana ^a   Le Lan Leguen, Anne ^a   Roth, Lucile ^a   Sola, Brigitte ^a  

^a UNIVERSITÉ DE CAEN   (France)

Author keywords

Cyclin D; Proliferation; shRNA

Indexed keywords

BORTEZOMIB; CYCLIN D1; CYCLIN D2; CYTOKININ; KINETIN; MESSENGER RNA; SHORT HAIRPIN RNA;

APOPTOSIS; B LYMPHOCYTE; BLOOD DISEASE; CELL COUNT; CELL CYCLE ARREST; CELL LINE; CELL LINEAGE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; GENE SEQUENCE; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRINAE; LETTER; MANTLE CELL LYMPHOMA; MYELOMA; MYELOMA CELL; OBSERVATION; PATHOGENESIS; PLASMID; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; UPREGULATION;

CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN D2; G1 PHASE; HUMANS; LYMPHOMA, MANTLE-CELL; MULTIPLE MYELOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; S PHASE;

EID: 73149116221     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.011460     Document Type: Letter

References (6)

1. Klier M, Anastasov N, Hermann A, Meindl T, Angermeier D, Raffeld M, et al. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia 2008;22:2097-105.
2. Chiles TC. Regulation and function of cyclin D2 in B lymphocytes subsets. J Immunol 2004;173:2901-7.
3. Carthon BC, Neumann CA, Das M, Pawlyk B, Li T, Geng Y, Sicinski P. Genetic replacement of cyclin D1 function in mouse development by cyclin D2. Mol Cell Biol 2005;25:1081-8.
4. Bogner C, Peschel C, Decker T. Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach. Leuk Lymphoma 2006;47:195-205.
5. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009;23:10-24.
6. Tiedemann RE, Mao X, Shi C-X, Zhu YX, Palmer SE, Sebag M, Marler R, Chesi M, Fonseca R, Bergsagel PL, Schimmer AD, Stewart AK. Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. J Clin Invest 2008;118:1750-64.